Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Websites that sell compounded GLP-1 RAs often partially inform or misinform consumers, including with respect to US FDA approval.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

The digital health unicorn sells its chronic condition management and musculoskeletal programs to employers and health plans ...

A new study published in  Physiology & Behavior   uncovers significant sensory implications of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), medications commonly prescribed ...

THURSDAY, Jan. 30, 2025 (HealthDay News) -- The absolute risk for thyroid cancer is low among patients receiving ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public debate.

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...